This Article Full Text Full Text (PDF) All Versions of this Article: 48/1/73    most recent 01.HYP.0000226046.58883.32v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ridker, P. M Search for Related Content PubMed PubMed Citation Articles by Ridker, P. M Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB HYDROCHLOROTHIAZIDE Related Collections Secondary prevention Risk Factors Clinical Studies Other Vascular biology

(Hypertension. 2006;48:73.)
© 2006 American Heart Association, Inc.

Original Articles

Valsartan, Blood Pressure Reduction, and C-Reactive Protein

Primary Report of the Val-MARC Trial

Paul M Ridker; Eleanor Danielson; Nader Rifai; Robert J. Glynn for the Val-MARC Investigators

From the Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Dr Paul Ridker, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave E, Boston, MA 02215. E-mail pridker{at}partners.org

Increased levels of high-sensitivity C-reactive protein (hsCRP) are associated with incident hypertension as well as cardiovascular events, and angiotensin II is a potent proinflammatory mediator. However, whether angiotensin receptor blockade lowers hsCRP is uncertain. We performed a randomized trial in which 1668 patients with stage 2 hypertension were treated with 160 mg valsartan or 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ) once daily for 2 weeks with forced titration to 320 mg valsartan or 320/12.5 mg valsartan/HCTZ for an additional 4 weeks. After 6 weeks, systolic blood pressure (–25 versus –18 mm Hg; P<0.001) and diastolic blood pressure (–14 versus –9 mm Hg; P<0.001) were reduced to a greater degree among those allocated to valsartan/HCTZ than to valsartan monotherapy. The median change in hsCRP was –0.12 mg/L among those allocated to valsartan compared with +0.05 mg/L among those allocated to valsartan/HCTZ, a 13.3% difference (P<0.001); this difference between valsartan and valsartan/HCTZ was present in all subgroups evaluated despite the fact that blood pressure reduction was greater in the combined therapy group. No relationship was observed between hsCRP reduction and blood pressure; in all analyses, the proportion of variation in change in hsCRP with valsartan monotherapy explained by change in blood pressure was <2%. Thus, in this prospective trial, valsartan reduced hsCRP levels in a manner independent of degree of blood pressure reduction. These data raise the hypothesis that angiotensin receptor blockade may have anti-inflammatory effects in addition to blood pressure–lowering effects.

Key Words: clinical trials • antihypertensive therapy • angiotensin antagonist

This article has been cited by other articles:

				J. Galle, E. Schwedhelm, S. Pinnetti, R. H. Boger, C. Wanner, and on behalf of the VIVALDI investigators Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3174 - 3183. [Abstract] [Full Text] [PDF]

				D. Conen, P. M. Ridker, S. Mora, J. E. Buring, and R. J. Glynn Risk of type 2 diabetes mellitus in those with hypertension: reply Eur. Heart J., April 1, 2008; 29(7): 953 - 954. [Full Text] [PDF]

				D Conen, B M Everett, R J Glynn, and P M Ridker Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial Heart, March 1, 2008; 94(3): e13 - e13. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, K. A. Jablonski, M. M. Rice, J. W. Warnica, M. J. Domanski, J. Hsia, B. J. Gersh, N. Rifai, P. M Ridker, et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease Circulation, March 27, 2007; 115(12): 1528 - 1536. [Abstract] [Full Text] [PDF]

				J. H. Revkin, C. L. Shear, H. G. Pouleur, S. W. Ryder, and D. G. Orloff Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future Pharmacol. Rev., March 1, 2007; 59(1): 40 - 53. [Abstract] [Full Text] [PDF]

				J. M. Luther, J. V. Gainer, L. J. Murphey, C. Yu, D. E. Vaughan, J. D. Morrow, and N. J. Brown Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor-Dependent Mechanism Hypertension, December 1, 2006; 48(6): 1050 - 1057. [Abstract] [Full Text] [PDF]

				Can an ARB Reduce BP and CRP Levels? Journal Watch Cardiology, August 9, 2006; 2006(809): 3 - 3. [Full Text]